Search PubMed⌕ Search

Biomedical subjects

C U Lowe

Publications and source records attributed to C U Lowe.

34 records · Page 2Linked to original sources
PubMed1966

Mucopolysaccharide from patients with cystic fibrosis of the pancreas.

Physical and immunologic methods were used to demonstrate the presence of an apparently unique glycoprotein in stool and tissue of patients having cystic fibrosis of the pancreas. The detection of a molecular structure specific for the disease is consistent with the apparent hereditary nature of the affection.

Adult↗
PubMedDate not supplied

O-specific side-chain toxin-protein conjugates as parenteral vaccines for the prevention of shigellosis and related diseases.

Only indirect evidence has been cited to document that lipopolysaccharide-mediated virulence at the bacterial level and serum antibodies to the O-specific side chain of the lipopolysaccharide molecule may prevent shigellosis. Our proposed use of the B subunit of Shiga toxin as a carrier protein is based upon evidence (even more indirect) that serum antitoxin may reduce the severity of dysentery and diarrhea. Because animal models of disease may provide information inapplicable to the prediction of vaccine-induced protective immunity, we suggest that clinical trials in the population at risk should be started after successful completion of the safety and immunogenicity phases of vaccine development in laboratory animals and in the target population. Clinical studies of shigella vaccines are difficult because of the many causes of dysentery in a population with a high rate of intestinal disease.

Animals↗
PubMedDate not supplied

The triple helix--NIH, industry, and the academic world.

Spectacular accomplishments in biomedical research have given birth to what is now perceived as a biological revolution, an epoch in which man has acquired the skill to manipulate the fundamental unit of heredity, the gene. This revolution carries with it the prospect of remarkable opportunities to improve the quality of life and to probe with increasing precision the mysteries of cellular organization and function. It comes, however, at a time when the opportunity to exploit this new knowledge may be limited by a significant reduction in federal support of basic research, and a situation which prompts universities and other centers of scientific activity to seek funding from industrial patrons. This trend has generated a new constellation of institutional challenges, for one apparent result of industrial sponsorship of university-based biomedical research is a threat to university governance as altered allegiances emerge and as the potential for financial gain appears almost limitless. This essay explores background issues leading to these new alliances, seeks to identify some of the central problems emerging for university administrators, faculty, and students, and then poses a key question: Can industrial support for university-based biomedical research fill the apparent short-fall in federal dollars in the foreseeable future? An analysis of available data indicates that this outcome is unlikely either now or in the years ahead.

DNA, Recombinant↗